ATE271040T1 - Substituierte pyridinderivate, deren herstellung und deren verwendung als modulatoren von acetylcholin-rezeptoren - Google Patents

Substituierte pyridinderivate, deren herstellung und deren verwendung als modulatoren von acetylcholin-rezeptoren

Info

Publication number
ATE271040T1
ATE271040T1 AT96913789T AT96913789T ATE271040T1 AT E271040 T1 ATE271040 T1 AT E271040T1 AT 96913789 T AT96913789 T AT 96913789T AT 96913789 T AT96913789 T AT 96913789T AT E271040 T1 ATE271040 T1 AT E271040T1
Authority
AT
Austria
Prior art keywords
disorders
disease
modulators
acetylcholine receptors
compounds
Prior art date
Application number
AT96913789T
Other languages
English (en)
Inventor
Nicholas D Cosford
Jean-Michel Vernier
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE271040T1 publication Critical patent/ATE271040T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT96913789T 1995-04-07 1996-04-04 Substituierte pyridinderivate, deren herstellung und deren verwendung als modulatoren von acetylcholin-rezeptoren ATE271040T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/419,597 US5585388A (en) 1995-04-07 1995-04-07 Substituted pyridines useful as modulators of acetylcholine receptors
PCT/US1996/005078 WO1996031475A2 (en) 1995-04-07 1996-04-04 Substituted pyridine derivatives, their preparation and their use as modulators of acetylcholine receptors

Publications (1)

Publication Number Publication Date
ATE271040T1 true ATE271040T1 (de) 2004-07-15

Family

ID=23662934

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96913789T ATE271040T1 (de) 1995-04-07 1996-04-04 Substituierte pyridinderivate, deren herstellung und deren verwendung als modulatoren von acetylcholin-rezeptoren

Country Status (9)

Country Link
US (3) US5585388A (de)
EP (1) EP0871615B1 (de)
JP (1) JP4138872B2 (de)
AT (1) ATE271040T1 (de)
AU (1) AU718517B2 (de)
CA (1) CA2217651A1 (de)
DE (1) DE69632916T2 (de)
ES (1) ES2224167T3 (de)
WO (1) WO1996031475A2 (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US20020052497A1 (en) * 2000-03-09 2002-05-02 Targacept, Inc. Compounds capable of activating cholinergic receptors
US6979695B2 (en) 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
US6437138B1 (en) 1996-06-06 2002-08-20 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
TR199901904T2 (xx) * 1996-12-10 1999-10-21 Abbott Laboratories 3-piridil enantiyomerleri ve bunlar�n analjezik olarak kullan�lmas�.
US6133253A (en) * 1996-12-10 2000-10-17 Abbott Laboratories 3-Pyridyl enantiomers and their use as analgesics
US5861423A (en) 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US5811442A (en) * 1997-02-21 1998-09-22 Bencherif; Merouane Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow
US6531606B1 (en) 1997-02-21 2003-03-11 Targacept, Inc. Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
WO1998053820A1 (en) 1997-05-29 1998-12-03 H. Lundbeck A/S Treatment of schizophrenia and psychosis
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US6362009B1 (en) 1997-11-21 2002-03-26 Merck & Co., Inc. Solid phase synthesis of heterocycles
EP1068186A2 (de) 1998-04-02 2001-01-17 Targacept, Inc. 3-pyridylalkoxyamine oder aryloxyalkylamine derivate als cholinergische agonisten
CA2317567A1 (en) * 1998-04-02 1999-10-14 R.J. Reynolds Tobacco Company Pharmaceutical compositions and methods for use
US7790757B2 (en) * 1998-06-16 2010-09-07 Targacept, Inc. Compounds capable of activating cholinergic receptors
US20050131034A1 (en) * 1998-06-16 2005-06-16 Caldwell William S. Compounds capable of activating cholinergic receptors
EP1086082B9 (de) * 1998-06-16 2005-03-02 Targacept, Inc. Arylsubstituierte olefinische amine und ihre verwendung als cholinergische rezeptoragonisten
US6232316B1 (en) 1998-06-16 2001-05-15 Targacept, Inc. Methods for treatment of CNS disorders
US6232326B1 (en) 1998-07-14 2001-05-15 Jodi A. Nelson Treatment for schizophrenia and other dopamine system dysfunctions
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
JP2003500402A (ja) * 1999-05-21 2003-01-07 アボット・ラボラトリーズ 中枢神経系薬として有用なアミノアザ環のヘテロ環置換体
KR100713572B1 (ko) * 1999-05-21 2007-05-02 아보트 러보러터리즈 중추 신경계 제제로서 유용한 헤테로사이클릭 치환된 아미노아자사이클 및 이를 포함하는 약제학적 조성물
US6833370B1 (en) 1999-05-21 2004-12-21 Abbott Laboratories Heterocycle substituted aminoazacycles useful as central nervous system agents
US20010031771A1 (en) 1999-05-24 2001-10-18 Gary Maurice Dull Pharmaceutical compositions and methods for use
CA2376061A1 (en) * 1999-06-07 2000-12-14 Targacept, Inc. Pharmaceutical compositions and methods for use
DE10005150A1 (de) * 2000-02-07 2001-08-09 Merck Patent Gmbh Verfahren zur Herstellung von 5-Arylnicotinaldehyden
US6809105B2 (en) 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
MY137020A (en) 2000-04-27 2008-12-31 Abbott Lab Diazabicyclic central nervous system active agents
US6458804B1 (en) 2001-01-26 2002-10-01 R.T. Alamo Venturesi, Llc Methods for the treatment of central nervous system disorders in certain patient groups
AU2002331229B2 (en) * 2001-09-19 2008-05-15 Merck Patent Gmbh Novel use of substituted aminomethyl chromans
AU2002360598B2 (en) * 2001-12-14 2008-02-14 Medical College Of Georgia Research Institute, Inc. Methods and compositions for treatment of central nervous system disorders
US7091357B2 (en) * 2001-12-26 2006-08-15 University Of Kentucky Research Foundation Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
MXPA03000145A (es) 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
US7176322B2 (en) 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
US6908935B2 (en) 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
EA009789B1 (ru) 2002-07-05 2008-04-28 Таргасепт, Инк. N-арилдиазаспирациклические соединения и способы их получения и применения
AU2003254016A1 (en) 2002-07-19 2004-02-09 Catholic Healthcare West Methods and compositions relating to chimeric nicotinic receptor subunits
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
JP4679514B2 (ja) * 2003-04-24 2011-04-27 メルク・シャープ・エンド・ドーム・コーポレイション Ａｋｔ活性の阻害剤
WO2004096131A2 (en) * 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
EP1678172B1 (de) 2003-10-15 2009-12-09 Targacept, Inc. Azabicyclische verbindungen zur linderung von schmerzen und zur behandlung von erkrankungen des zentralen nervensystems
BRPI0418712B8 (pt) * 2004-04-02 2021-06-22 Arterial Remodelling Tech Inc método para preparar uma montagem para fornecimento de um stent polimérico degradável e bioreabsorvível, montagem para fornecer um stent degradável e bioreabsorvível e método para preparar um stent polimérico degradável e bioreabsorvível
AU2005254800B2 (en) 2004-06-15 2010-12-09 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
AP2007003887A0 (en) 2004-07-23 2007-02-28 Pfizer Pyridine derivatives
CN101044134A (zh) 2004-09-20 2007-09-26 塔加西普特公司 具有烟碱性胆碱能受体活性的氮杂螺烯和氮杂螺烷化合物
UA88792C2 (ru) 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
US20090088433A1 (en) * 2005-01-26 2009-04-02 Bertrand Leblond Methods of using as analgesics 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
MX2007011105A (es) 2005-03-10 2007-10-08 Pfizer Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos.
CA2618700A1 (en) 2005-08-22 2007-03-01 Targacept, Inc. Heteroaryl-substituted diazatricycloalkanes, methods for its preparation and use thereof
TWI389889B (zh) 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
EP2021325A2 (de) 2006-05-09 2009-02-11 AstraZeneca AB Salzformen von (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amin
TWI454262B (zh) 2006-11-02 2014-10-01 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
JP2010510202A (ja) 2006-11-17 2010-04-02 ファイザー株式会社 置換ビシクロカルボキシアミド化合物
WO2008091588A1 (en) 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
TW200845977A (en) 2007-03-30 2008-12-01 Targacept Inc Sub-type selective azabicycloalkane derivatives
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
KR101565469B1 (ko) 2007-10-01 2015-11-03 코멘티스, 인코포레이티드 알츠하이머병의 치료를 위한 알파 7 니코틴 아세틸콜린 수용체 리간드로서 퀴누클리딘-4-일메틸 1ｈ-인돌-3-카르복실레이트 유도체
AR072899A1 (es) 2008-08-07 2010-09-29 Merck Sharp & Dohme Derivados de terpiridina-carboxamida antagonistas de receptores de orexina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del insomnio y la obesidad.
EP2350010B1 (de) * 2008-10-30 2014-03-26 Merck Sharp & Dohme Corp. Isonikotinamide als orexinrezeptorantagonisten
CN102232070A (zh) 2008-12-01 2011-11-02 塔加西普特公司 (r)-5-((e)-2-(吡咯烷-3-基乙烯基)嘧啶的合成和新的盐形式
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
TW201024283A (en) 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
BRPI1010600A2 (pt) 2009-05-15 2016-03-15 Novartis Ag aril piridina como inibidores de aldosterona sintase
EP2509982A1 (de) 2009-12-07 2012-10-17 Targacept, Inc. 3,6-diazabicyclo[3.1.1]heptane als neuronale nikotinische acetylcholinreceptorliganden
CN103180277A (zh) 2010-05-20 2013-06-26 塔格塞普特股份有限公司 制备芳基取代的烯属胺的新方法
NZ603966A (en) 2010-05-27 2015-03-27 Targacept Inc Nicotinic receptor non-competitive antagonists
WO2012125518A1 (en) 2011-03-14 2012-09-20 Targacept, Inc. Salt forms of 3 - cyclopropylcarbonyl - 3, 6 - diazabicyclo [3.1.1] heptane
WO2012129262A1 (en) 2011-03-23 2012-09-27 Targacept, Inc. Treatment of attention deficit/hyperactivity disease
TW201311698A (zh) 2011-08-22 2013-03-16 Targacept Inc 作為神經元菸鹼乙醯膽鹼受體配位體之１，４－二氮雜雙環［３．２．２］壬烷
US20170166561A1 (en) 2014-07-11 2017-06-15 Alpharmagen, Llc Quinuclidine compounds for modulating alpha7-nicotinic acetylcholine receptor activity
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
JP7221944B2 (ja) 2017-09-19 2023-02-14 メルク・シャープ・アンド・ドーム・エルエルシー ニコチン性アセチルコリン受容体のヘテロアリールアロステリックモジュレーター
CN119775199B (zh) * 2025-02-21 2025-08-01 澳门科技大学 一种抗炎小分子化合物及其合成方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2194567A (en) * 1938-02-28 1940-03-26 Pyridium Corp Esters of aminopyridine carboxylic acid and processes for producing the same
GB945824A (en) * 1960-09-02 1964-01-08 Merck Ag E ªÏ-(pyridyl-3)-or ªÏ-(piperidyl-3)-propanol and derivatives thereof and processes for their manufacture
DE1231704B (de) * 1963-12-19 1967-01-05 Josef Klosa Dipl Chem Dr Rer N Verfahren zur Herstellung neuer Diaryl-alkylaminoverbindungen mit heterocyclischen Ringen
NL6401902A (de) * 1964-02-27 1965-08-30
US3313822A (en) * 1965-07-14 1967-04-11 Warner Lambert Pharmaceutical Diphenyl substituted aminoalkyl pyridines
SE361663B (de) * 1971-04-28 1973-11-12 Haessle Ab
LU65414A1 (de) * 1972-05-24 1973-12-04
FR2187317B2 (de) * 1972-06-07 1975-06-20 Hexachimie
US4009174A (en) * 1972-12-08 1977-02-22 The Boots Company Limited Esters of substituted nicotinic acids
DE2364685C3 (de) * 1973-12-27 1978-06-15 Beiersdorf Ag, 2000 Hamburg Phenoxyäthylamine
GB1485919A (en) * 1975-08-12 1977-09-14 Grindstedvaerket As Pyridine derivatives
FR2341311A1 (fr) * 1976-02-20 1977-09-16 Parcor Derives de la pyridoxine
JPS52125170A (en) * 1976-04-12 1977-10-20 Yoshitomi Pharmaceut Ind Ltd Pyridine derivatives
US4444774A (en) * 1982-07-29 1984-04-24 American Cyanamid Company 7-Heteroaryl[1,2,4]triazolo[1,5-a]pyrimidines
IL100688A (en) * 1987-08-01 1995-08-31 Takeda Chemical Industries Ltd Intermediates for the production of unsaturated amines in position A and the process for their preparation
IT1231477B (it) * 1989-07-12 1991-12-07 Sigma Tau Ind Farmaceuti (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
CA2029497C (en) * 1989-11-08 2002-06-04 Kunihiro Ninomiya (Deceased) 4-acylaminopyridine derivative
US5418229A (en) * 1990-01-06 1995-05-23 Alker; David Muscarinic receptor antagonists
DE4038335A1 (de) * 1990-12-01 1992-06-04 Boehringer Mannheim Gmbh Neue pyridinderivate, verfahren zu ihrer herstellung und verwendung als arzneimittel
US5212188A (en) * 1992-03-02 1993-05-18 R. J. Reynolds Tabacco Company Method for treatment of neurodegenerative diseases
US5214060A (en) * 1992-04-10 1993-05-25 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5232932A (en) * 1992-05-21 1993-08-03 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
DE4232561A1 (de) * 1992-09-29 1994-03-31 Bayer Ag Bekämpfung von Fischparasiten
IL107184A (en) * 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
EP0637237B1 (de) * 1993-02-23 2004-05-19 Brigham And Women's Hospital, Inc. Calciumrezeptoraktive moleküle

Also Published As

Publication number Publication date
US5686473A (en) 1997-11-11
US5736560A (en) 1998-04-07
CA2217651A1 (en) 1996-10-10
WO1996031475A3 (en) 1997-02-06
AU718517B2 (en) 2000-04-13
AU5663696A (en) 1996-10-23
DE69632916T2 (de) 2005-07-14
JP4138872B2 (ja) 2008-08-27
EP0871615A1 (de) 1998-10-21
US5585388A (en) 1996-12-17
DE69632916D1 (de) 2004-08-19
ES2224167T3 (es) 2005-03-01
JPH11503430A (ja) 1999-03-26
EP0871615B1 (de) 2004-07-14
WO1996031475A2 (en) 1996-10-10

Similar Documents

Publication Publication Date Title
DE69632916D1 (de) Substituierte Pyridinderivate, deren Herstellung und deren Verwendung als Modulatoren von Acetylcholin-Rezeptoren
ATE248160T1 (de) Pyridin acetylcholin-rezeptor-modulatoren
DE69628333D1 (de) Neue substituierte aryl-verbindungen als acetylcholine receptors modulatoren
DE69528823D1 (en) Morpholinwirkstoffvorläufer als tachykininreceptorantagonisten
MX9706969A (es) 3-(1,2,3,6-tetrahidropiridin-4-il)-1h-indoles y 3-(piperidin-4-il)-1h-indoles sustituidos en la posicion 5: agonistas del 5-ht1f novedosos.
DE69616480D1 (de) Piperidinderivate als neurokininantagonisten
NO940927L (no) Kondenserte tricykliske nitrogenholdige heterocykler som substans-P-reseptor-antagonister
NO963785L (no) Fremgangsmåte for behandling av 5HT2B-reseptor-relaterte betingelser
AU8122791A (en) Benzimidazoles
AU1856397A (en) Heterocyclic derivatives as antidiabetic and antiobesity agents
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
RU94046364A (ru) Замещенные гетероциклы, способ их получения, фармокомпозиция, способ лечения
DE69232309D1 (de) Weitgehend reine rezeptorartige, tgf-beta-1-bindende moleküle und deren verwendungen
ATE245632T1 (de) Benzodiazepin derivate verwendbar als cck- rezeptoren antagonisten
WO2000027379A3 (en) Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives
ATE178886T1 (de) 1-aryl-2-acylamino-ethan-verbindungen und ihre verwendung als neurokinin- insbesondere als neurokinin-1-antagonisten
ATE188869T1 (de) Stabilisiertes sonnenschutzmittel
CA2336009A1 (en) Use of receptors of the rev-erb family to screen substances which are useful in the treatment of lipid metabolism dysfunctions
NO880405D0 (no) Fremgangsmaate til fremstilling av 3-fenyl-7h-tiazolo-/3,2-b//1,2,4/-tiazine-7-oner.
ATE111940T1 (de) Pulverlacke und die verwendung von ausgewählten bindemittelkombinationen für pulverlacke.
ATE294802T1 (de) 3-alkylimidazopyridine
DK0923549T3 (da) Methansulfonatsalt af et arylpiperazin afledt af tryptamin og solvater deraf til farmaceutisk anvendelse
DK159428C (da) Analogifremgangsmaade til fremstilling af 11-piperazinylcarbonylmethylen-5,6-dihydromorphantridin-6-oner
ATE139773T1 (de) Neue 1-aryl-4-piperazinyl- cyclohexancarbonsäurenitrile, ihre herstellung und verwendung
WO1999043807A3 (en) Human channel-related molecules

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties